ella

Drug Overview

In the modern landscape of women’s reproductive health, the ability to prevent an unintended pregnancy after a contraceptive failure or unprotected intercourse is a cornerstone of patient autonomy. Within the specialized Gynecology drug category, emergency contraception has evolved to provide options that are highly effective even several days after the event. Ella is a premier, prescription-only medication belonging to the Drug Class of Progesterone Receptor Modulator (EC).

As a sophisticated systemic Hormone Modulator, ella differs significantly from older, over-the-counter emergency pills. It is designed to offer a wider window of effectiveness and a higher level of reliability, particularly when administered closer to the time of expected ovulation. By interacting directly with the body’s natural hormone signaling, it provides a crucial “second chance” for women to maintain control over their reproductive timeline.

• Generic Name: Ulipristal acetate
• US Brand Names: ella
• International Brand Names: ellaOne
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Approved by the FDA in 2010 for use as an emergency contraceptive within 120 hours of unprotected intercourse or contraceptive failure.

What Is It and How Does It Work? (Mechanism of Action)

To understand the superior efficacy of ella, we must examine the intricate communication network between the brain and the ovaries, known as the hypothalamic-pituitary-ovarian (HPO) axis. In a typical menstrual cycle, the pituitary gland releases Luteinizing Hormone (LH). A sharp “surge” in LH is the direct physiological trigger that causes a mature follicle in the ovary to rupture and release an egg (ovulation).

Ella functions as a highly precise Targeted Therapy at the molecular level. It is a Selective Progesterone Receptor Modulator (SPRM). This means it has the unique ability to act as both an agonist (promoter) and an antagonist (blocker) of progesterone receptors, depending on the tissue and the hormonal environment.

1. Ovulation Delay via HPO Axis Modulation: The primary mechanism of ella is the inhibition or delay of ovulation. When a woman takes ella, the drug binds with high affinity to progesterone receptors in the brain and the ovaries. As a systemic Hormone Modulator, it interrupts the normal signaling that leads to the LH surge.
2. The Pre-Ovulatory Window: Unlike older emergency contraceptives (such as levonorgestrel), which lose effectiveness once LH levels begin to rise, ella remains effective even later in the cycle. At the molecular level, it can block the progesterone-induced signaling required for the follicle to rupture. Clinical research shows that ella can delay ovulation even when the LH surge has already started but has not yet reached its peak.
3. Endometrial Alteration: While its primary job is to stop the egg from being released, ella also causes temporary changes to the uterine lining (the endometrium). By modulating progesterone receptors in the uterus, it may theoretically make the lining less receptive, though evidence suggests that delaying ovulation is the overwhelming reason it prevents pregnancy.

It is vital to note that ella is a Targeted Therapy for preventing pregnancy, not ending one. It is not an “abortion pill” and will not interrupt an established pregnancy once implantation has occurred.

FDA-Approved Clinical Indications

ella is recognized globally as a high-efficacy intervention for time-sensitive reproductive care.

Primary Gynecological/Obstetric Indications

• Emergency Contraception: Indicated for the prevention of pregnancy following unprotected intercourse or a known contraceptive failure (such as a broken condom or missed birth control pills). It is uniquely approved for use up to 120 hours (5 days) after the event.

Off-Label / Endocrinological Indications

While ella is specifically packaged and dosed for emergency use, the active ingredient (ulipristal acetate) is studied and used in various other women’s health contexts:

• Uterine Fibroid Management: In many international markets (though under different brand names and dosing schedules), ulipristal acetate is used as a Targeted Therapy to shrink uterine fibroids and reduce the severe bleeding (menorrhagia) associated with them.
• Endometriosis Symptom Relief: Some specialized clinical trials have explored the use of SPRMs to suppress the growth of endometrial tissue outside the uterus and manage chronic pelvic pain.
• Fertility Preservation: Research is ongoing into how SPRMs might be used to “quiet” the reproductive system during certain medical treatments to protect future ovarian function.

Dosage and Administration Protocols

ella is designed as a single-intervention treatment. Because its efficacy is tied to the timing of ovulation, it should be taken as soon as possible after the unprotected event.

Specific Population Considerations:

• BMI and Efficacy: Unlike levonorgestrel-based pills, which may see a sharp decline in efficacy for women with a Body Mass Index (BMI) over 25 or 30, ella maintains a higher rate of pregnancy prevention in women with higher BMIs.
• Vomiting: If a patient vomits within 3 hours of taking ella, a second 30 mg dose should be administered immediately, as the first may not have been absorbed.
• Repeat Use: Ella is not intended for regular use. If unprotected sex occurs again in the same cycle after taking ella, a woman can still become pregnant.

Clinical Efficacy and Research Results

Clinical data (2020–2026) confirms that ella is the most effective oral emergency contraceptive. It maintains efficacy up to 120 hours after intercourse, reducing pregnancy risk to 1 to 2% versus 5 to 8% without intervention. Meta-analyses show ella is more effective than levonorgestrel, especially 72–120 hours post-intercourse, halving pregnancy risk. It is also uniquely capable of delaying ovulation up to the LH surge, making it more reliable near peak fertility

Safety Profile and Side Effects

Ella has a well-established safety profile and does not carry a “Black Box Warning.” Because it is a single-dose Hormone Modulator, most side effects are temporary and mild.

Common Side Effects (>10%)

• Headache: Reported by nearly 18 percent of users.
• Nausea: Affects approximately 12 percent of patients.
• Abdominal Pain: Lower pelvic cramping (12 percent).
• Dysmenorrhea: Painful menstruation during the next cycle.
• Fatigue and Dizziness: Temporary loss of energy or lightheadedness.

Serious Adverse Events

Serious events are extremely rare with a single dose. However, clinicians monitor for:

• Ectopic Pregnancy: While ella does not cause ectopic pregnancy, if the medication fails and a pregnancy occurs, any woman experiencing severe one-sided pelvic pain must be evaluated to rule out a tubal pregnancy.
• Cycle Disturbance: Most women will experience their next period at the expected time, but ella can cause the next period to be up to 7 days early or 7 days late.

Management Strategies:

If nausea is a significant concern, patients may take the tablet with a small meal. For the management of post-treatment cramping, standard over-the-counter pain relievers are generally sufficient. Patients should be advised that if their period is more than one week late, they must perform a pregnancy test.

Research Areas

While Ella is used for emergency contraception, research (2024–2026) is exploring future applications of Selective Progesterone Receptor Modulators (SPRMs). Studies are investigating low-dose ulipristal acetate as an “on-demand” therapy before intercourse and its potential in regenerative medicine. By modulating progesterone receptors, SPRMs may pause cycles, reduce inflammation, and create an optimal uterine environment for stem cell or tissue repair therapies in women with scarring or Asherman’s syndrome.

Disclaimer: The studies and potential applications of Selective Progesterone Receptor Modulators (SPRMs) described above are currently in the research and exploratory phase and are not yet applicable to routine clinical practice or professional patient care.

Patient Management and Practical Recommendations

Pre-treatment tests

• Pregnancy Test: Not required before taking ella unless there is a reason to believe the woman is already pregnant from an earlier act of intercourse.
• Pelvic Ultrasound: Generally not required for emergency use.

Precautions during treatment

• Breastfeeding: Ulipristal acetate is excreted in breast milk. It is currently recommended that breastfeeding mothers express and discard their milk for 24 hours after taking the medication.
• Hormonal Birth Control Interaction: Because ella blocks progesterone receptors, taking it along with your regular birth control (which contains progestins) can make both medications less effective. Patients should wait 5 days after taking ella before restarting or starting a regular hormonal contraceptive. Use a barrier method (condoms) during this waiting period.

“Do’s and Don’ts” list

• DO take the pill as soon as possible; every hour matters for efficacy.
• DO use a backup method (condoms) for every act of intercourse until your next period.
• DO seek medical attention if you have severe abdominal pain after taking ella.
• DON’T take ella if you are already pregnant; it is not an abortion pill.
• DON’T use ella as your primary, regular method of birth control.
• DON’T take a levonorgestrel-based emergency pill in the same cycle after taking ella, as they may interfere with each other.

Legal Disclaimer

The medical information provided in this guide is for informational purposes only and does not replace professional medical advice from a qualified healthcare provider. ella is a prescription medication and should only be taken under the guidance of a physician. While highly effective, no contraceptive method is 100 percent guaranteed. If you suspect you are pregnant or have had a medical emergency, seek professional care immediately. Always consult with your gynecologist to discuss which emergency contraception option is right for your specific health history.